Emicizumab in Patients With Acquired Hemophilia A
Public ClinicalTrials.gov record NCT05345197. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial
Study identification
- NCT ID
- NCT05345197
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Washington
- Other
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Interventions
- emicizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2022
- Primary completion
- Jun 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Nov 4, 2025
2022 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Hemophilia and Thrombosis Treatment Center | San Diego | California | 92121 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Emory University | Atlanta | Georgia | 30308 | — |
| Bleeding and Clotting Disorders Institute | Peoria | Illinois | 61614 | — |
| Indiana Hemophilia and Thrombosis Center, Inc. | Indianapolis | Indiana | 46260 | — |
| Tulane University | New Orleans | Louisiana | 70112-2632 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Penn Blood Disorders Program, Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Hemophilia Center of Western Pennsylvania | Pittsburgh | Pennsylvania | 15213 | — |
| University of Vermont Medical Center | Burlington | Vermont | 05401 | — |
| UVA Comprehensive Cancer Center | Charlottesville | Virginia | 22908 | — |
| Washington Center for Bleeding Disorders | Seattle | Washington | 98101 | — |
| Versiti Inc. | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05345197, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05345197 live on ClinicalTrials.gov.